Press Releases
-
Monon Bioventures receives nearly $400,00 funding to develop Purdue-discovered glioblostoma treatment
Monon Bioventures receives funding to develop glioblostoma treatment
Sep 27, 2022
-
Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts
Sep 27, 2022
-
Quanticate partners with Cancer Research UK to launch DETERMINE Study
Sep 26, 2022
-
Heart pacing company Ceryx Medical partners with Osypka Medical
Ceryx Medical Limited has announced a partnership with Berlin-based Osypka Medical to develop a heart pacing device that will change the way patients with heart failure and other cardiac conditions are treated.
Sep 26, 2022
-
Creative Biostructure Uncovers Insights for Pathology Research with Advanced iEM Platform
Sep 26, 2022
-
Lifeasible Released Rare Plant Tissue Culture Service to for Research Use
Sep 26, 2022
-
Matexcel Provides a Wide Range of Metal Oxide Products for Research Use
Sep 26, 2022
-
Bora Pharmaceuticals partners with TaiRx, Inc. to manufacture breakthrough anticancer drug
Sep 26, 2022
-
BioIVT Acquires Fidelis Research
This transaction increases BioIVT's global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.
Sep 25, 2022
-
Abzena strengthens R&D capabilities to support rapid antibody discovery
For further information, images, and interview opportunities, please contact Kristy Harmer at ramarketing: kristy.harmer@ramarketingpr.com | +44 (0)191 222 1242 | ramarketingpr.com | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing About Abzena Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com
Sep 22, 2022
-
Zebrafish Disease Models: Accelerating Human Disease Studies and Biomedical Research
Sep 22, 2022
-
Microbiosci Offers Real-time PCR Kits to Support Research Applications in Viral Detection
Sep 22, 2022
-
CRISPR/Cas9 Platform Provides Accurate Gene Knockout Mouse Models for Immunology Research and Drug Discovery
Sep 22, 2022
-
Creative Bioarray Provides Cell Patterning Customization and Detection Services for Drug Screening
Sep 22, 2022
-
DDA Platform Offers A Wide Range of in Vitro and in Vivo Assays to Cover Early Stage Drug Discovery
Sep 22, 2022
-
Creative Bioarray Designs Comprehensive Tools and Protocols to Construct Animal Disease Models
Sep 22, 2022
-
Creative Enzymes Offers Products to Support the Clinical and Research Use of Liver Function Evaluation
Sep 21, 2022
-
Creative Enzymes Announces the Launch of Kex2 Protease from Saccharomyces Cerevisiae, Recombinant
Sep 6, 2022
-
Creative Proteomics Cytokine Accelerates Your Project with Its Colony Stimulating Factor Detection Service
Sep 21, 2022
-
Pronalyse Unveils Insightful Metabolite Identification Services of Biopharmaceuticals
Sep 21, 2022






